Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Sunesis Pharmaceutic (SNSS)

Sunesis Pharmaceutic (SNSS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 96,255
  • Shares Outstanding, K 18,093
  • Annual Sales, $ 2,070 K
  • Annual Income, $ -23,330 K
  • 60-Month Beta 2.21
  • Price/Sales 29.96
  • Price/Cash Flow N/A
  • Price/Book 5.09
Trade SNSS with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.39
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 03/09/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview

Details
  • Implied Volatility 0.00%
  • Historical Volatility 127.87%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.29
  • Number of Estimates 1
  • High Estimate -0.29
  • Low Estimate -0.29
  • Prior Year -0.50
  • Growth Rate Est. (year over year) +42.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.35 +126.38%
on 01/28/21
7.09 -24.93%
on 02/24/21
+2.29 (+75.58%)
since 01/22/21
3-Month
1.33 +300.00%
on 11/25/20
7.09 -24.93%
on 02/24/21
+3.96 (+291.18%)
since 11/24/20
52-Week
1.12 +375.00%
on 11/06/20
11.30 -52.92%
on 02/26/20
-3.88 (-42.17%)
since 02/24/20

Most Recent Stories

More News
Viracta Therapeutics Announces Closing of Merger with Sunesis Pharmaceuticals and $65M Private Placement

, /PRNewswire/ -- Therapeutics, Inc.  (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the closing of its merger with Sunesis Pharmaceuticals, Inc....

SNSS : 5.32 (+24.30%)
VIRX : 12.68 (-4.52%)
Viracta Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering the Use of its Combination Product Candidate for the Treatment of Epstein-Barr Virus-associated Lymphoma

, /PRNewswire/ -- Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that the U.S. Patent and Trademark Office (USPTO)...

SNSS : 5.32 (+24.30%)
Viracta Therapeutics to Participate in Upcoming Virtual Investor Conferences

, /PRNewswire/ --  Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that the Company will participate in the upcoming...

SNSS : 5.32 (+24.30%)
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of SNSS, LOAC, FBSS, and CPAH Mergers

Rigrodsky & Long, P.A. announces that it is investigating:

SNSS : 5.32 (+24.30%)
LOAC : 12.48 (-0.95%)
FBSS : 20.57 (+2.30%)
CPAH : 3.48 (+0.43%)
ALERT: Halper Sadeh LLP Investigates TDY, TCP, BEAT, HCAP, SNSS; Shareholders Are Encouraged to Contact the Firm

, /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

TDY : 370.63 (-1.12%)
TCP : 30.21 (+1.65%)
BEAT : 71.96 (+0.08%)
HCAP : 8.18 (-0.93%)
SNSS : 5.32 (+24.30%)
SHAREHOLDER ALERT: WeissLaw LLP Reminds HLIX, XLNX, SNSS, and AKER Shareholders About Its Ongoing Investigations

, /PRNewswire/ --

HLIX : 0.8400 (+9.09%)
XLNX : 123.51 (-4.96%)
SNSS : 5.32 (+24.30%)
AKER : 2.91 (-3.32%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Mergers - PNM, TNAV, SNSS, ZAGG, ELY

, /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

PNM : 47.10 (-1.26%)
TNAV : 4.79 (unch)
SNSS : 5.32 (+24.30%)
ZAGG : 4.29 (+0.70%)
ELY : 27.72 (-2.74%)
SUNESIS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Sunesis Pharmaceuticals, Inc. - SNSS

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed merger of Sunesis Pharmaceuticals, Inc. (NasdaqGS: SNSS)...

SNSS : 5.32 (+24.30%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Companies - AKER, INFO, SNSS, WORK, WDR

, /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

AKER : 2.91 (-3.32%)
INFO : 89.49 (-2.44%)
SNSS : 5.32 (+24.30%)
WORK : 40.25 (-1.64%)
WDR : 25.09 (-0.04%)
SHAREHOLDER ALERT: WeissLaw LLP Reminds NGA, FIII, and SNSS Shareholders About Its Ongoing Investigations

, /PRNewswire/ -- 

NGA : 17.85 (-8.04%)
FIII : 10.18 (-2.40%)
SNSS : 5.32 (+24.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. It has built a broad product candidate portfolio through internal discovery and in-licensing...

See More

Key Turning Points

3rd Resistance Point 9.13
2nd Resistance Point 8.11
1st Resistance Point 6.71
Last Price 5.32
1st Support Level 4.30
2nd Support Level 3.28
3rd Support Level 1.88

See More

52-Week High 11.30
Fibonacci 61.8% 7.41
Fibonacci 50% 6.21
Last Price 5.32
Fibonacci 38.2% 5.01
52-Week Low 1.12

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar